Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 12, 2023 08:00 ET
|
Vaccitech plc
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
April 17, 2023 09:00 ET
|
Vaccitech plc
VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human...
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
March 28, 2023 08:00 ET
|
Vaccitech plc
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen...
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments
March 24, 2023 08:06 ET
|
Vaccitech plc
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development...
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
March 20, 2023 08:00 ET
|
Vaccitech plc
VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs)Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6...
Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer
January 30, 2023 08:00 ET
|
Vaccitech plc
Dr. Pelletier joins leadership team to continue the advancement of Vaccitech’s diverse clinical pipeline and partnerships, bringing more than 15 years’ experience in pharmaceuticals and academia in...
Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases
November 21, 2022 10:31 ET
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application...
Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 10, 2022 16:30 ET
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview...
Vaccitech to Present at Upcoming November Investors Conferences
November 09, 2022 08:00 ET
|
Vaccitech plc
OXFORD, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies...
Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B
November 07, 2022 08:00 ET
|
Vaccitech plc
VTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial. VTP-300 as a monotherapy and in...